ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is being investigated for its potential use in the treatment of autoimmune diseases such as psoriasis and rheumatoid arthritis.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted